Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 303, 38-47
Abstract
No abstract availableKeywords
Funding Information
- University of Adelaide
This publication has 75 references indexed in Scilit:
- A highly secreted sulphamidase engineered to cross the blood‐brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIAEMBO Molecular Medicine, 2013
- Drosophila Heparan Sulfate, a Novel DesignJournal of Biological Chemistry, 2012
- Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo diseaseEuropean Journal of Human Genetics, 2009
- Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidosesEuropean Journal of Human Genetics, 2009
- An Atg1/Atg13 Complex with Multiple Roles in TOR-mediated Autophagy RegulationMolecular Biology of the Cell, 2009
- Oxidative Stress and Autophagy in the Regulation of Lysosome-Dependent Neuron DeathAntioxidants & Redox Signaling, 2009
- Autophagy in neurodegeneration and developmentBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008
- Motor Deficit in a Drosophila Model of Mucolipidosis Type IV due to Defective Clearance of Apoptotic CellsCell, 2008
- Ref(2)P, the Drosophila melanogaster homologue of mammalian p62, is required for the formation of protein aggregates in adult brainJournal of Cell Biology, 2008
- A genome-wide transgenic RNAi library for conditional gene inactivation in DrosophilaNature, 2007